FilingReader Intelligence

Legend Biotech announces positive 5-year CARVYKTI survival data

June 4, 2025 at 05:07 PM UTCBy FilingReader AI

GenScript Biotech Corporation (HKEX:1548) announced that its associate, Legend Biotech, released new five-year survival data for CARVYKTI in the CARTITUDE-1 study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data showed that, notably, one-third of patients with relapsed/refractory multiple myeloma experienced sustained progression-free survival for five years or more after a single CARVYKTI infusion, without maintenance therapy. Further CARTITUDE-4 subgroup analyses presented at ASCO highlighted consistent survival benefit across various cytogenetic risk groups as early as second-line therapy. Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors were also featured in poster presentations at ASCO.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Genscript Biotech Corp publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →